Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer

Neoplasia

Volumn 8, Issue 2, 2006, Pages 79-88

  Goon, P K Y ^a,b   Lip, G Y H ^a   Boos, C J ^a   Stonelake, P S ^b   Blann, A D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Circulating endothelial cells; Endothelial microparticles; Endothelial progenitor cells

Indexed keywords

TUMOR MARKER;

ANGIOGENESIS; BLOOD CLOTTING DISORDER; CANCER; CANCER CLASSIFICATION; CONSENSUS; DRUG MONITORING; ENDOTHELIUM CELL; EXOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; STEM CELL; TUMOR GROWTH;

EID: 33646395092     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05592     Document Type: Article

References (94)

1. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
2. Blann AD (2004). Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 33, 256-261.
3. De Cicco M (2004). The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50, 187-196.
4. Goon PKY, Boos CJ, and Lip GYH (2005). Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 51, 531-538 (review).
5. + endothelial precursor cells. Circ Res 88, 167-174.
6. Burger PE, Coetzee S, McKeehan WL, Kan M, Cook P, Fan Y, Suda T, Hebbel RP, Novitsky N, Muller WA, et al. (2002). Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood 100, 3527-3535.
7. Rafii S, Lyden D, Benezra R, Hattori K, and Heissig B (2002). Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2, 826-835.
8. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, and Tedgui A (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101, 841-843.
9. George F, Brisson C, Poncelet P, Laurent JC, Massot O, Arnoux D, Ambrosi P, Klein-Soyer C, Cazenave JP, and Sampol J (1992). Rapid isolation of human endothelial cells from whole blood using S-Endo 1 monoclonal antibody coupled to immunomagnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 67, 147-153.
10. Solovey A, Lin Y, Browne P, Choong, Wayner E, and Hebble RP (1997). Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337, 1584-1590.
11. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, and Bertolini F (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658-3661.
12. Khan SS, Solomon MA, and McCoy JP Jr, (2005). Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64, 1-8.
13. Hobson B and Denekamp J (1984). Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49, 405-413.
14. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, and Lip GYH (2004). Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilatation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110, 1794-1798.
15. Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, and Maglione W (2004). Circulating endothelial cells as markers of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50, 1296-1304.
16. Kas-Deelen AM, Harmsen MC, de Maar EF, Oost-Kort WW, Tervaert JW, Van der Meer J, Van Son WJ, and The TH (2000). Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 58, 2533-2542.
17. Lee KW, Lip GYH, Tayebjee M, Foster W, and Blann AD (2005). Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105, 526-532.
18. Makin A, Chung NA, Silverman SH, and Lip GY (2004). Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Eur Heart J 25, 371-376.
19. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune EJ, et al. (2004). Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103, 3677-3683.
20. Ruegg C, Yilmaz A, Bieller G, Bamat J, Chaubert P, and Lejeune FJ (1998). Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumour vasculature induced by TNF and IFN-gamma. Nat Med 4, 408-414.
21. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, and Bunyaratvej A (2002). Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumour necrosis factor in thalassaemia. Am J Hematol 70, 100-106.
22. Mutin M, Canavy I, Blann AD, Bory M, Sampol J, and Dignat-George F (1999). Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93, 2951-2958.
23. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, and Voest EE (2004). Increased levels of viable of circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15, 139-145.
24. Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HM, and Voest EE (2004). Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett 213, 241-248.
25. Kim HK, Song KS, Kim HO, Chung JH, Lee KR, Lee YJ, Lee DH, Lee ES, Kim HK, Ryu KW, et al. (2003). Circulating numbers of endothelial progenitor cells in patients with gastric and breast cancer. Cancer Lett 198, 83-88.
26. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, et al. (2005). Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105, 3286-3294.
27. de Vos FY, Willemse PH, de Vries EG, and Gietema JA (2004). Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 30, 495-513.
28. Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, Sondermann D, Andreesen R, and Holler E (2002). Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 100, 334-340.
29. Nicolson GL and Custead SE (1985). Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 45, 331-336.
30. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, et al. (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the VEGF receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase 1 studies. J Clin Oncol 21, 3955-3964.
31. Gunsilius E, Tschmelitsch J, and Petzer AL (2001). Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 7, 443.
32. Adams J, Carder PJ, Downey S, Forbes MA, McLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al. (2000). Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60, 2898-2905.
33. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, and Bertolini F (2003). Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9, 377-382.
34. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Shultz L, and Bertolini F (2003). Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522, 83-97.
35. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, et al. (2002). A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100, 905-911.
36. Martin TA, Watkins G, Lane J, and Jiang WG (2005). Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 46, 422-430.
37. Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, et al. (2004). Assessing tumor angiogenesis: increasing VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 64, 4373-4377.
38. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, and Colotta F (1994). Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 127, 537-546.
39. Lampugnani MG and Dejana E (1997). Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol 9, 674-682.
40. Crosby CV, Fleming PA, Argraves WS, Corada M, Zanetta L, Dejana E, and Drake CJ (2005). VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 105, 2771-2776.
41. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, and Williamson RC (1995). Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346, 1004-1005.
42. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, and Nawroth PP (1994). Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumour cells in mice. J Clin Invest 94, 1320-1327.
43. Yu JL, May L, Lhotak V, Sharzhad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, and Rak JW (2005). Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105, 1734-1741.
44. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, and Suzuki H (1998). Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 80, 894-898.
45. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, and Imamura M (2000). Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 88, 295-301.
46. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, and Pribluda VS (2004). Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 103, 3374-3380.
47. Contrino J, Hair G, Kreutzer DL, and Rickles FR (1996). In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2, 209-215.
48. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, and Pinedo HM (2000). Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6, 166-171.
49. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatterman G, and Isner JM (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
50. + cells identifies a population of functional endothelial precursors. Blood 95, 952-958.
51. Rafii S and Lyden D (2003). Therapeutic stem and progenitor cell transplantation for organ vascularisation and regeneration. Nat Med 9, 702-712.
52. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Ito Y, and Isner M (1999). VEGF contributes to postnatal neovascularisation by bone marrow derived endothelial progenitor cells. EMBO J 18, 3964-3972.
53. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, et al. (2001). Impaired recruitment of bone marrow derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7, 1194-1201.
54. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, et al. (2000). In vitro differentiation of endothelial cells from AC 133-positive progenitor cells. Blood 95, 3106-3112.
55. Lin Y, Weisdorf DJ, Solovey A, and Hebbel RP (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105, 71-77.
56. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T (2001). Mobilisation of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103, 2776-2779.
57. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kiekens L, Gertstenstein M, Fahrig M, Vanderhoeck A, Harpal K, Eberhardt C, et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
58. Rafii S, Heissig B, and Hattori K (2002). Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 9, 631-641.
59. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, and Itescu S (2001). Neovascularisation of ischaemic myocardium by human bone marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodelling and improves cardiac function. Nat Med 7, 430-436.
60. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, and Isner JM (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation. Circ Res 85, 221-228.
61. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, et al. (2001). Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vascular and hematopoietic stem cells. J Exp Med 193, 1005-1014.
62. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, et al. (2003). Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischaemic neovascularisation. Circulation 107, 1322-1328.
63. Okazaki T, Ebihara S, Takahashi H, Asada M, Kanda A, and Sasaki H (2005). Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis. J Immunol 174, 7531-7538.
64. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, and Asahara T (1999). Ischaemia and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularisation. Nat Med 5, 434-438.
65. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, Rafii D, and Lyden D (2002). Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13, 61-67.
66. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, and Nickenig G (2004). Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109, 220-226.
67. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, and Lau CP (2003). Angiogenesis in ischaemic myocardium by intramyocardial autologous bone genesis marrow mononuclear cell implantation. Lancet 361, 47-49.
68. Risau W (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
69. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii D, Haimovitz-Friedman A, Fuks Z, and Kolesnick R (2003). Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159.
70. Crosby JR, Kaminski WE, Schatterman G, Martin PJ, Raines EW, Seifert RA, and Bowen-Pope DF (2000). Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87, 728-730.
71. De Palma M, Venneri MA, Roca C, and Naldini L (2003). Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9, 789-795.
72. Jain RK and Duda DG (2003). Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 3, 515-516.
73. Göthert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, Green AR, Gottgens B, Izon DJ, and Begley CG (2004). Genetically tagging endothelial cells in vivo vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104, 1769-1777.
74. Rehman J, Li J, Orschell CM, and March KL (2003). Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169.
75. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101-111.
76. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JA, de Waal RM, Van Marck E, Magnani E, et al. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38, 1564-1579.
77. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, and Kerbel RS (2003). Maximum tolerable dose and low dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating progenitor cells. Cancer Res 63, 4342-4346.
78. Schuch G, Heymach JV, Nomi M, Machcluf M, Force J, Atala A, Eder JP Jr, Folkman J, and Soker S (2003). Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63, 8345-8350.
79. Eder JP, Clark J, Supko J, Puchalski TA, Garcia-Carbonero R, Ryan DP, Schulman LN, Proper J, Kirvan M, Rattner B, et al. (2002). A phase 1 trial of recombinant human Endostatin. J Clin Oncol 20, 3772-3784.
80. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147.
81. Hamilton KK, Hattori R, Esmon CT, and Sims PJ (1990). Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 265, 3809-3814.
82. Combes V, Simon A, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, and Dignat-George F (1999). In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 104, 93-102.
83. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstmann LL, and Ahn YS (2003). Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 109, 175-180.
84. Laurence J, Mitra D, Steiner M, Staiano-Coico L, and Jaffe E (1996). Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood, 3245-3254.
85. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, and Tedgui A (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101, 841-843.
86. Freyssinet JM (2003). Cellular microparticles: what are they bad or good for? J Thromb Haemost 1, 1655-1662.
87. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, and Dolo V (2002). Shedding of the matrix metalloproteinases MMP-2, MMP-9 and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160, 673-680.
88. Casciola-Rosen L, Rosen A, Petri M, Petri M, and Schlissel M (1996). Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Nat Acad Sci USA 93, 1624-1629.
89. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, and Hebbel RP (2003). Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102, 2678-2683.
90. Jimenez JJ, Jy W, Mauro LM, Horstmann LL, Soderland C, and Ahn YS (2003). Endothelial microparticles released in thrombotic thrombocytopaenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 123, 896-902.
91. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, and Mallat Z (2001). Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 104, 2649-2652.
92. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, et al. (2005). Circulating endothelial cells: biomarker of vascular disease. Thromb Haemost 93, 1-9.
93. Garmy-Susini B and Varner JA (2005). Circulating endothelial progenitor cells. Br J Cancer 93, 855-858.
94. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, and Dimmeler S (2001). Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103, 2885-2890.